Please Wait...

Molecular Marker Lab

Specialized biomarker services backed by unrivalled scientific expertise, fully validated technology and the highest quality standard.

Molecular Marker Lab - Highly Specialized Biomarker Services for Clinical Trials

Bioclinica Lab is a highly specialized service provider of biochemical marker analysis to the pharmaceutical and biotech industries. Our extensive panel of validated biomarkers serve as surrogate endpoints in support of global, multi-site, clinical trials – from phase I to IV – across a wide range of therapeutic areas. With over 15 years of experience, over 400 clinical trials supported, and over 1 million samples analyzed, we are committed to providing quality services for your clinical study.

BIOMARKER MENU

View our complete list of validated Biomarker assays.
LEARN MORE

BIOMARKER ANALYSIS

Automated methods for Biomarker detection and analysis.
LEARN MORE

CLINICAL LAB SERVICES

In house scientific and technical expertise.
LEARN MORE

QUALITY ASSURANCE

Rigorous QA and CAP accreditation.
LEARN MORE

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (Yesterday)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (2 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (4 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (4 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (4 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (4 days ago)

Latest Blogs: